Literature DB >> 15706440

Roles of cyclophilins in cancers and other organ systems.

Qizhi Yao1, Min Li, Hui Yang, Hong Chai, William Fisher, Changyi Chen.   

Abstract

Cyclophilins are originally identified as cellular binding proteins for the immunosuppressive drug cyclosporin A. Many cyclophilins, including CypA, CypB, CypC, CypD, and Cyp40, have been discovered and shown to be ubiquitously distributed in many types of cells and organ systems. Recent investigations have uncovered many important properties and functions for cyclophilins including peptidyle-prolyl-isomerase activity and protein folding/repair; maintaining mitochondrial functions and involvement in apoptosis; roles in regulation of T-cell function and inflammation; interaction with CD147; and pathogenesis of vascular disease, human immunodeficiency virus infection, and rheumatoid arthritis. Furthermore, the expression and functions of cyclophilins may be correlated with tumor biology of several types of cancers including pancreatic carcinoma. Molecular mechanisms of cyclophilin-mediated biologic events and future directions of research are discussed in this review. Understanding the roles of cyclophilins in cancers and other organ systems will be crucial in determining clinical applications for the treatment or diagnosis of human diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706440     DOI: 10.1007/s00268-004-7812-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  60 in total

1.  Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23.

Authors:  B C Freeman; D O Toft; R I Morimoto
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

2.  Cyclophilin-A is involved in excitotoxin-induced caspase activation in rat neuronal B50 cells.

Authors:  Michela Capano; Sukaina Virji; Martin Crompton
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

Review 3.  The biochemistry of programmed cell death.

Authors:  G Kroemer; P Petit; N Zamzami; J L Vayssière; B Mignotte
Journal:  FASEB J       Date:  1995-10       Impact factor: 5.191

Review 4.  Rapamycin: a novel immunosuppressive macrolide.

Authors:  S N Sehgal; K Molnar-Kimber; T D Ocain; B M Weichman
Journal:  Med Res Rev       Date:  1994-01       Impact factor: 12.944

5.  Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer.

Authors:  B K Ward; P J Mark; D M Ingram; R F Minchin; T Ratajczak
Journal:  Breast Cancer Res Treat       Date:  1999-12       Impact factor: 4.872

6.  Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6.

Authors:  F Berditchevski; S Chang; J Bodorova; M E Hemler
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

7.  Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase.

Authors:  B Steinmann; P Bruckner; A Superti-Furga
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

8.  Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction.

Authors:  X X Zheng; T B Strom; A W Steele
Journal:  Transplantation       Date:  1994-07-15       Impact factor: 4.939

9.  [Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides].

Authors:  G Fischer; H Bang; C Mech
Journal:  Biomed Biochim Acta       Date:  1984

10.  The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins.

Authors:  I Marzo; C Brenner; N Zamzami; S A Susin; G Beutner; D Brdiczka; R Rémy; Z H Xie; J C Reed; G Kroemer
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more
  32 in total

Review 1.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Cyclophilin D in mitochondrial pathophysiology.

Authors:  Valentina Giorgio; Maria Eugenia Soriano; Emy Basso; Elena Bisetto; Giovanna Lippe; Michael A Forte; Paolo Bernardi
Journal:  Biochim Biophys Acta       Date:  2009-12-21

Review 3.  Towards identifying novel anti-Eimeria agents: trace elements, vitamins, and plant-based natural products.

Authors:  Frank Wunderlich; Saleh Al-Quraishy; Holger Steinbrenner; Helmut Sies; Mohamed A Dkhil
Journal:  Parasitol Res       Date:  2014-09-04       Impact factor: 2.289

4.  A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.

Authors:  Yoshihiro Ishikawa; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

5.  Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection.

Authors:  Xiaochen Tian; Chao Zhao; Hongguang Zhu; Weimin She; Jiming Zhang; Jing Liu; Lanjuan Li; Shusen Zheng; Yu-Mei Wen; Youhua Xie
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Authors:  T Tiepolo; A Angelin; E Palma; P Sabatelli; L Merlini; L Nicolosi; F Finetti; P Braghetta; G Vuagniaux; J-M Dumont; C T Baldari; P Bonaldo; P Bernardi
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

7.  Structural, biochemical, and in vivo characterization of the first virally encoded cyclophilin from the Mimivirus.

Authors:  Vu Thai; Patricia Renesto; C Andrew Fowler; Darin J Brown; Tara Davis; Wanjun Gu; David D Pollock; Dorothee Kern; Didier Raoult; Elan Z Eisenmesser
Journal:  J Mol Biol       Date:  2007-08-29       Impact factor: 5.469

8.  Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis.

Authors:  Li Wang; Cong-hua Wang; Jun-feng Jia; Xiao-kui Ma; Yu Li; Hong-bin Zhu; Hao Tang; Zhi-nan Chen; Ping Zhu
Journal:  J Clin Immunol       Date:  2009-09-30       Impact factor: 8.317

9.  PPIB mutations cause severe osteogenesis imperfecta.

Authors:  Fleur S van Dijk; Isabel M Nesbitt; Eline H Zwikstra; Peter G J Nikkels; Sander R Piersma; Silvina A Fratantoni; Connie R Jimenez; Margriet Huizer; Alice C Morsman; Jan M Cobben; Mirjam H H van Roij; Mariet W Elting; Jonathan I M L Verbeke; Liliane C D Wijnaendts; Nick J Shaw; Wolfgang Högler; Carole McKeown; Erik A Sistermans; Ann Dalton; Hanne Meijers-Heijboer; Gerard Pals
Journal:  Am J Hum Genet       Date:  2009-09-24       Impact factor: 11.025

10.  Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A.

Authors:  Jennifer Schlegel; Jasmina S Redzic; Christopher C Porter; Vyacheslav Yurchenko; Michael Bukrinsky; Wladimir Labeikovsky; Geoffrey S Armstrong; Fengli Zhang; Nancy G Isern; James DeGregori; Robert Hodges; Elan Zohar Eisenmesser
Journal:  J Mol Biol       Date:  2009-06-03       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.